Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma. ZUMA-5 is a single-arm, multicentre, phase 2 trial...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The lancet oncology Ročník 23; číslo 1; s. 91 - 103
Hlavní autori:	Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, Neelapu, Sattva S
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 01.01.2022 Elsevier Limited
Edícia:	Lancet Oncol
Predmet:	Adverse events Aged Antigens Biological Products - adverse effects Biological Products - therapeutic use CD19 antigen CD20 antigen Cell therapy Chemotherapy Chimeric antigen receptors Clinical trials Cyclophosphamide Cytokines Female Fludarabine Hematology, Oncology, and Palliative Medicine Humans Immunotherapy, Adoptive Laboratories Leukapheresis Life Sciences Lymphocytes T Lymphoma Lymphoma, Non-Hodgkin - drug therapy Male Manufacturing Middle Aged Monoclonal antibodies Multiple organ dysfunction syndrome Non-Hodgkin's lymphoma Patients Recurrence Response rates United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!